Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

被引：37
|
作者：
Chen, Jinxia [1 ]
Xu, Zhiyuan [1 ,2 ,3 ]
Hu, Can [1 ,2 ,3 ]
Zhang, Shengjie [1 ,2 ,3 ]
Zi, Mengli [1 ]
Yuan, Li [1 ,2 ,3 ]
Cheng, Xiangdong [1 ,2 ,3 ]
机构：
[1] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp,Dept Gastr S, Hangzhou, Peoples R China
[2] Zhejiang Canc Hosp, Zhejiang Prov Res Ctr Upper Gastrointestinal Trac, Hangzhou, Peoples R China
[3] Zhejiang Canc Hosp, Zhejiang Key Lab Prevent Diag & Therapy Upper Gas, Hangzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
Claudin-18.2; gastrointestinal (GI) tract; monoclonal antibody; antibody-drug conjugate (ADC); chimeric antigen receptor T (CAR-T); PANCREATIC DUCTAL ADENOCARCINOMA; T CELL THERAPY; GASTRIC-CANCER; CLAUDIN-18; GENE; EXPRESSION; PROTEIN; PROLIFERATION; ANTIBODY; PHOSPHORYLATION; ZOLBETUXIMAB;
D O I：
10.3389/fonc.2023.1132319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18.2 and its clinical significance in GI cancer. We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18.2 in clinical research.
引用
收藏
页数：17
相关论文
共 50 条
  • [1] Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
    Wu, Jun
    Lu, Jinghua
    Chen, Qiuyue
    Chen, Haojie
    Zheng, Yongqiang
    Cheng, Minggang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [2] Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications
    Wang, Yang
    Ma, Lin
    Kuang, Zijun
    Li, Dengke
    Yang, Jian
    Liu, Yuxia
    Zhang, Lan
    Li, Zheng
    Li, Qingnuan
    MOLECULAR PHARMACEUTICS, 2024, 21 (08) : 3838 - 3847
  • [3] Exploration of radionuclide labeling of a novel scFv-Fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment
    Li, Dapeng
    Ding, Lei
    Chen, Yan
    Wang, Zilei
    Zeng, Ziqing
    Ma, Xiaopan
    Huang, Haifeng
    Li, Hongjun
    Qian, Xueming
    Yang, Zhi
    Zhu, Hua
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 266
  • [4] Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
    Zhu, Guoyun
    Foletti, Davide
    Liu, Xiaohui
    Ding, Sheng
    Witt, Jody Melton
    Hasa-Moreno, Adela
    Rickert, Mathias
    Holz, Charles
    Aschenbrenner, Laura
    Yang, Amy H.
    Kraynov, Eugenia
    Evering, Winston
    Obert, Leslie
    Lee, Chenyu
    Sai, Tao
    Mistry, Tina
    Lindquist, Kevin C.
    Van Blarcom, Thomas
    Strop, Pavel
    Chaparro-Riggers, Javier
    Liu, Shu-Hui
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] CLDN18.2-targeting STAR-T cell therapy for pancreatic cancer: a strategy to minimize gastric off-tumor toxicity compared to CLDN18.2 CAR-T
    Zhang, Wei
    Zeng, Miao
    Ma, Xingyu
    Chen, Jinghong
    Qiao, Jingqiao
    He, Ziqian
    Zhong, Guocheng
    Li, Yisheng
    Yu, Li
    ONCOGENE, 2025,
  • [6] A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
    Yue, Jingying
    Shao, Shuai
    Zhou, Jie
    Luo, Wenting
    Xu, Yanling
    Zhang, Qinbin
    Jiang, Jing
    Zhu, Marie M.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (01) : 106 - 115
  • [7] Targeting the PD-1 pathway: a new hope for gastrointestinal cancers
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 749 - 759
  • [8] Targeting cancers in the gastrointestinal tract: role of capecitabine
    Saif, Muhammad Wasif
    ONCOTARGETS AND THERAPY, 2009, 2 : 29 - 41
  • [9] A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
    Jingying Yue
    Shuai Shao
    Jie Zhou
    Wenting Luo
    Yanling Xu
    Qinbin Zhang
    Jing Jiang
    Marie M Zhu
    Investigational New Drugs, 2024, 42 : 106 - 115
  • [10] Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment
    Ratti, Margherita
    Orlandi, Elena
    Hahne, Jens Claus
    Vecchia, Stefano
    Citterio, Chiara
    Anselmi, Elisa
    Toscani, Ilaria
    Ghidini, Michele
    BIOMEDICINES, 2023, 11 (10)
12345